The relation between Helicobacter pylori and ulcerative colitis

Turkish Journal of Medical Sciences

Volumn 44, Issue 5, 2014, Pages 820-823

  Caner, Sedat ^a   Altinbaş, Akif ^a   Yeşil, Yusuf ^b   Beyazit, Yavuz ^b   Yilmaz, Bariş ^c   Yüksel, Osman ^c  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^c DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Helicobacter pylori; Immunosuppressive drugs; Ulcerative colitis

Indexed keywords

ADULT; COLITIS, ULCERATIVE; DRUG EFFECTS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; STOMACH MUCOSA;

ADULT; COLITIS, ULCERATIVE; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED;

EID: 84905672393     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1305-39     Document Type: Article

References (20)

1. Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 2012;160: 29-44.
2. Altinbas A, Koybasioglu F, Aktas E, Yilmaz B, Coban S. Ulcerative colitis triggered by pegylated interferon alone therapy for chronic hepatitis C. Inflamm Bowel Dis 2011;17: 1050.
3. Louis E, Van Kemseke C, Latour P, Belaiche J, Reenaers C. Genetics and environment in chronic inflammatory bowel diseases. Rev Med Liege 2012; 67: 298-304 (article in French with English abstract).
4. Dogruman-Al F, Simsek Z, Boorom K, Ekici E, Sahin M, Tuncer C, Kustimur S, Altinbas A. Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara, Turkey. PLoS One 2010; 5: e15484.
5. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008; 40: 619-626.
6. Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J Gastroenterol 2012; 47: 609-618.
7. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15 (Suppl. 1): 60-68.
8. Hasni SA. Role of Helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol 2012; 24: 429-434.
9. el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, McColl KE. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 1994; 35: 1385-1388.
10. Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 439-443.
11. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol 2003; 36: 22-25.
12. Triantafillidis JK, Gikas A, Apostolidiss N, Merikas E, Mallass E, Peros G. The low prevalence of Helicobacter infection in patients with inflammatory bowel disease could be attributed to previous antibiotic treatment. Am J Gastroenterol 2003; 98: 1213-1214.
13. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.
14. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048.
15. Naber AH, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med 2003; 61: 105-110.
16. Wagtmans MJ, Witte AM, Taylor DR, Biemond I, Veenendaal RA, Verspaget HW, Lamers CB, van Hogezand RA. Low seroprevalence of Helicobacter pylori antibodies in historical sera of patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 712-718.
17. Parente F, Molteni P, Bollani S, Maconi G, Vago L, Duca PG, Rembacken B, Axon AT, Bianchi Porro G. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A crosssectional study with matching. Scand J Gastroenterol 1997; 32: 1140-1146.
18. Stenson WF, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol 1984; 33: 407-412.
19. Taha AS, Sturrock RD, Russell RI. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1732-1735.
20. Halme L, Rautelin H, Leidenius M, Kosunen TU. Inverse correlation between Helicobacter pylori infection and inflammatory bowel disease. J Clin Pathol 1996; 49: 65-67.